Mortality was not considered in the analysis because of the comparatively young treatment age of patients in Pathway CH-1, the limited 5-year timeframe of the analysis, and because no significant differences in mortality were expected between the SPG stimulation and medical management cohorts.
Reducing the timeframe of the analysis to a follow-up period of 3.5 years resulted in an ICER of €40,058, at an added discounted cost of €9,537.
For the simulated medical treatment cohort, we assumed the baseline utility would be maintained over the full timeframe of the analysis.
The timeframe of this analysis was the four-year period of the intervention.
However, because of the timeframe of our analysis, we feel that this is not an unrealistic assumption.
While Medicare home healthcare delivery has changed since 2002, it typically provides services for a much shorter period of time (often 60 days or less) than the 22-month timeframe of our analysis.
The following information was extracted from each article: model type, timeframe of the analysis, perspective, baseline scenario, estimated coverage of the preventative strategy, need for revaccination, age at which vaccination begins, efficacy of the strategy, costs, reduction in mortality attributable to CC, and reduction in the incidence of CC.
In the Netherlands, the mean daily cost estimate of exenatide twice daily was based on a weighted average of the 5 μg and 10 μg packs sold during the timeframe of the analysis, according to the estimated market share proportions of 11.3% and 88.7%, respectively.
The usual timeframe for analysis of inflammatory response is one week after injection.
The population dynamics observed will of course vary both according to the timeframe and the resolution of analysis.
